칠레 위암 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 : 칠레 위암 치료 시장

칠레 위암 치료 시장은 2022년에서 2029년의 예측 기간 동안 상당한 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 7.7%의 CAGR로 성장하고 있으며 2029년까지 2,375만 달러에 도달할 것으로 예상한다고 분석했습니다. 위장관 종양, 림프종 및 선암의 증가로 약물 및 치료에 대한 수요가 증가하여 위암 치료 시장 성장을 견인할 것으로 예상됩니다.

위암은 악성(암) 세포가 위 점막에 형성되는 질병입니다. 나이, 식단, 위 질환은 위암 발병 위험에 영향을 미칠 수 있습니다. 위암의 증상에는 소화불량, 위 불편감 또는 통증이 있습니다.

위벽은 5개의 조직 층으로 구성되어 있습니다. 가장 안쪽 층에서 가장 바깥쪽 층까지 위벽의 층은 점막, 점막하층, 근육, 장막하(결합 조직), 장막입니다. 위암은 점막에서 시작하여 자라면서 바깥층으로 퍼집니다. 위암은 수년에 걸쳐 천천히 진행되는 경향이 있습니다. 진짜 암이 발생하기 전에, 암이 완전히 발생하기 전에 위 내벽(점막)에서 전암성 변화가 종종 발생합니다. 이러한 초기 변화는 증상을 유발하는 경우가 드물기 때문에 종종 감지되지 않습니다. 위의 여러 부분에서 암이 발생하면 다른 증상이 나타날 수 있으며 다른 결과를 초래하는 경향이 있습니다. 암의 위치도 치료 옵션에 영향을 미칠 수 있습니다.

칠레 전역에서 위암 발생률이 증가하고 의료비 지출이 늘어나면서 시장 성장이 촉진될 것으로 예상됩니다.

칠레 위암 치료 시장 범위 및 시장 규모

칠레 위암 치료 시장은 유형, 단계, 치료, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

• On the basis of type, the Chile gastric cancer treatment market is segmented into adenocarcinoma, gastrointestinal stromal tumor, carcinoid tumor, lymphoma, and others. In 2021, adenocarcinoma segment is expected to dominate the market owing to increasing prevalence of this specific gastric cancer type in Chile.
• On the basis of stages, the Chile gastric cancer treatment market is segmented into stage III, stage II, stage IV, stage I, and others. In 2022, stage III segment is expected to dominate the market because of the high drug consumption in this particular stage.
• On the basis of treatment, the Chile gastric cancer treatment market is segmented into chemotherapy, targeted therapy, immune checkpoint inhibitors, and others. In 2022, chemotherapy segment is expected to dominate the market due to the overall survival rate and low recurrence rate of gastric cancer associated with this treatment.
• On the basis of route of administration, the Chile gastric cancer treatment market is segmented into parenteral, oral, and others. In 2022, parenteral segment is expected to dominate the market as it is the most efficient way of treating cancer. Moreover, various treatments are available in injectable form.
• On the basis of end user, the Chile gastric cancer treatment market is segmented into hospitals, specialty clinics, research & academic institutes, and others. In 2022, hospitals segment is expected to dominate the market as it provides patients with the best healthcare services. Hospitals in developed and developing countries are highly demanding for advanced cancer treatment due to the rising healthcare concerns of the patients.
• On the basis of distribution channel, the Chile gastric cancer treatment market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, hospital pharmacy segment is expected to dominate the market as they are the primary source of various drugs recommended by the oncologist for gastric cancer treatment and brand satisfaction.

Chile Gastric Cancer Treatment Market Country Level Analysis

Chile gastric cancer treatment market is analyzed and market size information is provided by the type, stages, treatment, route of administration, end user, and distribution channel as referenced above.

The country covered in the Chile Gastric cancer treatment market report is Chile.

Targeted products segment in Chile is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 owing to increasing drug approvals and its ability to be administered as a standalone drug especially in certain stages.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Chile brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Gastric cancer is Boosting the Market Growth

The Chile gastric cancer treatment market also provides you with detailed market analysis for every country growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the period 2020 to 2029.

Competitive Landscape and Chile Gastric Cancer Treatment Market Share Analysis

Chile Gastric cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Chile gastric cancer treatment market

Some of the major companies, which are dealing in the Chile gastric cancer treatment market are Pfizer Inc., Merck KGaA, Celnova Pharma, Teva Pharmaceutical Industries Limited, AstraZenaca, Bristol-Myers Squibb Company, Sanofi, Laboratorio Varifarma S.A. , Tecnofarma SA., F. Hoffmann-La Roche Ltd., Biotoscana Group, Megalabs Chile SA among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Various contracts and agreements are also initiated by the companies worldwide which are further accelerating the Chile gastric cancer treatment market growth.

For instance,

• 2020년 5월, Eli Lilly and Company는 미국 식품의약국(FDA)이 CYRAMZA®(라무시루맙 주사액, 10mg/mL 용액)를 erlotinib과 병용하여 상피 성장 인자 수용체(EGFR) 엑손 19 결손 또는 엑손 21(L858R) 돌연변이가 있는 전이성 비소세포 폐암(NSCLC) 환자의 1차 치료제로 승인했다고 발표했습니다. 이 승인으로 CYRAMZA는 현재 특정 유형의 폐암, 간암, 위암 및 대장암을 치료하기 위한 6개의 FDA 승인을 받았습니다. 이 회사의 신약 승인으로 시장에서의 판매와 수요가 증가하여 향후 판매가 증가할 것입니다.
• 2019년 11월, Pfizer, Inc.는 Upjohn이라는 사업부가 Mylan NV와 결합되어 Viatris라는 새로운 회사를 만들었다고 발표했습니다. 이 회사의 사업부와 Mylan NV의 결합으로 제품 포트폴리오가 늘어나 시장에서 제품 수요가 증가했습니다.

SKU-67213